GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

被引：0
|
作者：
Coates, L. C. [1 ]
Ritchlin, C. T. [2 ]
Gossec, L. [3 ]
Helliwell, P. [4 ]
Rahman, P. [5 ]
Hsia, E. C. [6 ,7 ]
Kollmeier, A. [8 ]
Xu, X. L. [8 ]
Karyekar, C. [9 ]
Shawi, M. [9 ]
Noel, W. [10 ]
Jiang, Y. [11 ]
Sheng, S. [11 ]
Wang, Y. [11 ]
Mease, P. J. [12 ,13 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[2] Univ Rochester, Med Ctr, Dept Med AllergyImmunol & Rheumatol, Rochester, NY 14642 USA
[3] Sorbonne Univ, Rheumatol, Paris, France
[4] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[5] Mem Univ Newfoundland, Craig L Dobbin Genet Res Ctr, St John, NF, Canada
[6] Janssen Res & Dev LLC, Immunol, Spring House, PA USA
[7] Univ Penn, Rheumatol, Philadelphia, PA 19104 USA
[8] Janssen Res & Dev LLC, Immunol, La Jolla, CA USA
[9] Janssen Res & Dev LLC, Immunol, Horsham, PA USA
[10] Janssen Res & Dev LLC, Immunol, Brussels, Belgium
[11] Janssen Res & Dev LLC, Biostat, Spring House, PA USA
[12] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[13] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.167
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1024
引用
收藏
页码：781 / 782
页数：2
相关论文
共 50 条
  • [21] GUSELKUMAB PROVIDES CONSISTENT AND DURABLE PAIN IMPROVEMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF 2 PHASE 3, RANDOMIZED, CONTROLLED CLINICAL TRIALS
    Nash, P.
    Tam, L. S.
    Tsai, W. C.
    Leung, Y. Y.
    Furtner, D.
    Sheng, S.
    Wang, Y.
    Shawi, M.
    Kollmeier, A.
    Sherlock, J.
    Cua, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 839 - 840
  • [22] GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND NON-WORK ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS THROUGH 1 YEAR OF A PHASE 3 TRIAL
    Curtis, J.
    Mcinnes, I.
    Peterson, S.
    Agarwal, P.
    Yang, F.
    Kollmeier, A.
    Hsia, E. C.
    Han, C.
    Tillett, W.
    Mease, P. J.
    Rahman, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 782 - 783
  • [23] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
    Deodhar, Atul
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth C.
    LANCET, 2018, 391 (10136): : 2213 - 2224
  • [24] Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
    Nash, Peter
    Tam, Lai-Shan
    Tsai, Wen-Chan
    Leung, Ying-Ying
    Furtner, Daniel
    Sheng, Shihong
    Wang, Yanli
    Shawi, May
    Kollmeier, Alexa
    Sherlock, Jonathan
    Cua, Daniel
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2769 - 2772
  • [25] Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two Year Results from a Phase 3 Trial
    Helliwell, Philip S.
    Lespessailles, Eric
    Shuler, Catherine
    Mallbris, Lotus
    Erickson, Janelle
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [26] IXEKIZUMAB PROVIDES SUSTAINED IMPROVEMENT IN SIGNS AND SYMPTOMS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: TWO YEAR RESULTS FROM A PHASE 3 TRIAL
    Helliwell, P.
    Lespessailles, E.
    Shuler, C. L.
    Mallbris, L.
    Erickson, J.
    Fleischmann, R.
    Moyano, Sebastian
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S159 - S159
  • [27] Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naive Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis
    Helliwell, Philip
    Gladman, Dafna D.
    Chakravarty, Soumya D.
    Kafka, Shelly
    Karyekar, Chetan S.
    You, Yin
    Kavanaugh, Arthur
    Gensler, Lianne S.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [28] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial
    Mease, Philip J.
    Kavanaugh, Arthur
    Reimold, Andreas
    Tahir, Hasan
    Rech, Juergen
    Hall, Stephen
    Geusens, Piet
    Pascale, Pellet
    Delicha, Evie Maria
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [29] CHANGES IN SERUM CYTOKINES AND COLLAGEN PROTEINS CORRELATE WITH DURABILITY OF GUSELKUMAB EFFICACY AND CONTINUED DISEASE IMPROVEMENT THROUGH 2 YEARS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Siebert, S.
    Schett, G.
    Raychaudhuri, S. P.
    Guma, M.
    Chen, W.
    Gao, S.
    Chakravarty, S. D.
    Shawi, M.
    Rahman, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1763 - 1764
  • [30] CONSISTENT EFFICACY IN PATIENT SUBGROUPS ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS: RESULTS FROM A PHASE 2 STUDY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    McInnes, Iain
    Helliwell, Philip
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Xu, Xie L.
    Xu, Stephen
    Wang, Yuhua
    Hsia, Elizabeth C.
    Deodhar, Atul
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1277 - 1278
12345